NRSN
NeuroSense Therapeutics Ltd. · Healthcare
0.83
9.21%(+0.07)
Market Closed1.00
20.48%(+0.17)
After HoursLast Updated: — ET
52W L: $0.6352W H: $2.60
$0.80
CHG-0.06 (-6.76%)
H$1.03
L$0.63
VOL2.7M
NRSN (1h)
NeuroSense Therapeutics Ltd. · Healthcare
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantage Results published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activity Advancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readout CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Eisenberg Or
officer: Chief Financial Officer
200,000 SH @ $0.00
2026-03-26
Eisenberg Or
officer: Chief Financial Officer
0 SH @ $0.00
2026-03-18
Eisenberg Or
officer: Chief Financial Officer
0 SH @ $0.00
2026-03-18
Eisenberg Or
officer: Chief Financial Officer
0 SH @ $0.00
2026-03-18
Eisenberg Or
officer: Chief Financial Officer
66,666 SH @ $0.75
2024-08-15
Eisenberg Or
officer: Chief Financial Officer
21,000 SH @ $0.03
2021-07-01
Mandil-Levin Revital
director
0 SH @ $0.00
2026-03-18
Mandil-Levin Revital
director
0 SH @ $0.00
2026-03-18